Pharmacists in Florida will be allowed to prescribe certain medications from a restricted formulary beginning May 1, following approval of a proposal by the Florida State Pharmacy and Osteopathic Medical Examiner Boards on April 11. The proposal had earlier passed the state's board of medicine on April 6. The proposal submitted to the three state medical boards had been drafted by Florida's Pharmacist Prescribing Cmte. The cmte. was established to set a restrictive formulary for pharmacist prescribing, pursuant to a law that passed the state legislature last spring. Florida is the first state to permit general pharmacist prescribing outside a hospital setting without physician supervision. The proposal explicitly excludes injectable drugs and oral products for pregnant or nursing women. It also provides that patients "be advised that they should seek the advice of an appropriate health care provider if their present condition, symptom, or complaint does not improve upon completion of the drug regimen," and it disallows refills and supplies for more than 34 days. Pharmacists are required to personally dispense the drugs they have prescribed. The proposal applies only to Rx drugs; nonRx drugs are exempt from the rule's requirements and "shall be recommended as OTC products." Under the law, the state's boards of medicine, pharmacy, and osteopathy had to approve any Pharmacist Prescribing Cmte. regulation for establishing conditions for pharmacist prescribing. The support given to the latest pharmacist prescribing proposal by the three boards followed two rejections of earlier cmte. proposals. Profiles on all patients for whom a pharmacist prescribes a drug must be maintained for seven years under the draft regulation. The patient profile must contain a "statement regarding the patient's medical history" and current complaint, and a description of the "patient's chief complaint in the patient's own words." Chart omitted.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
